Clinical Trials Logo
  1. Home
  2. Other
  3. NCT01453465
  4. Details
NCT01453465 Clinical Trial

Biomarker Study in Samples From Patients With Malignant Rhabdoid Tumor of the Kidney or Atypical Teratoid Rhabdoid Tumor

Childhood Atypical Teratoid/Rhabdoid Tumor Clinical Trial

Official title:
Gene Expression (GE) and MicroRNA (MIRNA) Expression Profiles of Malignant Rhabdoid Tumors (MRT) of the Kidney (RTK) and Atypical Teratoid Rhabdoid Tumor (ATRT)

Clinical Trial Details — Status: Withdrawn

Administrative data
NCT number NCT01453465
Other study ID # ABTR12B1
Secondary ID NCI-2011-03468CD
Status Withdrawn
Phase
First received
Last updated
Start date November 1, 2011

Study information
Verified date October 2017
Source Children's Oncology Group
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This research trial studies biomarkers in samples from patients with rhabdoid tumor of the kidney and atypical teratoid rhabdoid tumor. Studying biomarkers of tissue samples from patients with cancer in the laboratory may help doctors learn more about changes the occur in DNA and identify biomarkers related to cancer.

Description:

PRIMARY OBJECTIVES:

I. To determine if there are molecular differences between rhabdoid tumor of the kidney (RTK) and the atypical teratoid rhabdoid tumor (ATRT).

OUTLINE:

Archived tumor tissue samples are analyzed for gene expression profile and microRNA profile.

Recruitment information / eligibility
Status Withdrawn
Enrollment 0
Est. completion date
Est. primary completion date December 1, 2011
Accepts healthy volunteers No
Gender All
Age group N/A and older
Eligibility Inclusion Criteria:

- Samples of RTK and ATRT provided by the Children?s Oncology Group (COG)

Study Design

Related Conditions & MeSH terms

Intervention

Other:
• Laboratory Biomarker Analysis
Correlative studies

Locations
Country Name City State
United States Childrens Oncology Group Philadelphia Pennsylvania

Sponsors (2)
Lead Sponsor Collaborator
Children's Oncology Group National Cancer Institute (NCI)

Country where clinical trial is conducted

United States, 

Outcome
Type Measure Description Time frame Safety issue
Primary Molecular differences between RTK and the ATRT Up to 3 months
See also
  Status Clinical Trial Phase
Completed NCT00100880 - Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors Phase 1
Terminated NCT01088763 - Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia Phase 1
Completed NCT00326664 - AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors Phase 1
Completed NCT02444546 - Wild-Type Reovirus in Combination With Sargramostim in Treating Younger Patients With High-Grade Relapsed or Refractory Brain Tumors Phase 1
Completed NCT00946335 - ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors Phase 1
Terminated NCT02684071 - Phase II Study of Intraventricular Methotrexate in Children With Recurrent or Progressive Malignant Brain Tumors Phase 2
Completed NCT01076530 - Vorinostat and Temozolomide in Treating Young Patients With Relapsed or Refractory Primary Brain Tumors or Spinal Cord Tumors Phase 1
Completed NCT00919750 - Collecting and Storing Blood and Brain Tumor Tissue Samples From Children With Brain Tumors
Completed NCT00653068 - Combination Chemotherapy, Radiation Therapy, and an Autologous Peripheral Blood Stem Cell Transplant in Treating Young Patients With Atypical Teratoid/Rhabdoid Tumor of the Central Nervous System Phase 3
Completed NCT00217412 - Vorinostat With or Without Isotretinoin in Treating Young Patients With Recurrent or Refractory Solid Tumors, Lymphoma, or Leukemia Phase 1